Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 264

1.

Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.

Gunderson CC, Fader AN, Carson KA, Bristow RE.

Gynecol Oncol. 2012 May;125(2):477-82. doi: 10.1016/j.ygyno.2012.01.003. Epub 2012 Jan 11. Review.

PMID:
22245711
2.

[Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].

Yu M, Shen K, Yang JX, Huang HF, Wu M, Pan LY, Lang JH, Lian LJ.

Zhonghua Fu Chan Ke Za Zhi. 2006 Apr;41(4):242-5. Chinese.

PMID:
16759458
3.

[Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].

Cao DY, Yu M, Yang JX, Shen K, Huang HF, Cheng NH, Sun ZY, Deng CY, Yu Q, He FF.

Zhonghua Fu Chan Ke Za Zhi. 2013 Jul;48(7):519-22. Chinese.

PMID:
24284224
4.

Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.

Kudesia R, Singer T, Caputo TA, Holcomb KM, Kligman I, Rosenwaks Z, Gupta D.

Am J Obstet Gynecol. 2014 Mar;210(3):255.e1-4. doi: 10.1016/j.ajog.2013.11.001. Epub 2013 Nov 8.

PMID:
24211482
5.

Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential.

Pronin SM, Novikova OV, Andreeva JY, Novikova EG.

Int J Gynecol Cancer. 2015 Jul;25(6):1010-4. doi: 10.1097/IGC.0000000000000467.

PMID:
25950126
6.

Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.

Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, Kwon YS, Lee IH, Lim KT, Lee KH, Shim JU, Mok JE, Kim TJ.

Int J Gynecol Cancer. 2009 Aug;19(6):1068-73. doi: 10.1111/IGC.0b013e3181aae1fb.

PMID:
19820370
7.

Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review.

Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C.

Gynecol Oncol. 2004 Oct;95(1):133-8. Review.

PMID:
15385122
8.

Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.

Simpson AN, Feigenberg T, Clarke BA, Gien LT, Ismiil N, Laframboise S, Massey C, Ferguson SE.

Gynecol Oncol. 2014 May;133(2):229-33. doi: 10.1016/j.ygyno.2014.02.020. Epub 2014 Feb 19.

PMID:
24561246
9.
10.

Hormonal therapy for women with stage IA endometrial cancer of all grades.

Park JY, Kim DY, Kim TJ, Kim JW, Kim JH, Kim YM, Kim YT, Bae DS, Nam JH.

Obstet Gynecol. 2013 Jul;122(1):7-14. doi: 10.1097/AOG.0b013e3182964ce3.

PMID:
23743459
11.

Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.

Zhou R, Yang Y, Lu Q, Wang J, Miao Y, Wang S, Wang Z, Zhao C, Wei L.

Gynecol Oncol. 2015 Dec;139(3):424-8. doi: 10.1016/j.ygyno.2015.09.078. Epub 2015 Sep 30.

PMID:
26428941
12.

Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy.

Penner KR, Dorigo O, Aoyama C, Ostrzega N, Balzer BL, Rao J, Walsh CS, Cass I, Holschneider CH.

Gynecol Oncol. 2012 Mar;124(3):542-8. doi: 10.1016/j.ygyno.2011.11.004. Epub 2011 Nov 10.

PMID:
22079678
13.

Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.

Chen M, Jin Y, Li Y, Bi Y, Shan Y, Pan L.

Int J Gynaecol Obstet. 2016 Jan;132(1):34-8. doi: 10.1016/j.ijgo.2015.06.046. Epub 2015 Oct 1.

PMID:
26493012
14.
15.

Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma.

Hubbs JL, Saig RM, Abaid LN, Bae-Jump VL, Gehrig PA.

Obstet Gynecol. 2013 Jun;121(6):1172-80. doi: 10.1097/AOG.0b013e31828d6186.

PMID:
23812449
16.

The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study.

Pashov AI, Tskhay VB, Ionouchene SV.

Gynecol Endocrinol. 2012 Jul;28(7):559-61. doi: 10.3109/09513590.2011.649813. Epub 2012 Feb 2.

PMID:
22296608
17.

Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin.

Park JY, Lee SH, Seong SJ, Kim DY, Kim TJ, Kim JW, Kim JH, Kim YM, Kim YT, Bae DS, Nam JH.

Gynecol Oncol. 2013 Apr;129(1):7-11. doi: 10.1016/j.ygyno.2012.12.037. Epub 2012 Dec 30.

PMID:
23283299
18.

Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.

Ohyagi-Hara C, Sawada K, Aki I, Mabuchi S, Kobayashi E, Ueda Y, Yoshino K, Fujita M, Tsutsui T, Kimura T.

Arch Gynecol Obstet. 2015 Jan;291(1):151-7. doi: 10.1007/s00404-014-3417-z. Epub 2014 Aug 14. Review.

PMID:
25118836
19.

Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome.

Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, Hataeg M, Kodama S, Kuzuya K, Sato S, Nishimura T, Hiura M, Nakano H, Iwasaka T, Miyazaki K, Kamura T.

Cancer Lett. 2001 Jun 10;167(1):39-48.

PMID:
11323097
20.

[Endometrial adenocarcinoma in women 40 years old or younger by treatment with progestins: report of 6 cases and review of the literatures].

Wang HY, Shen L, Sun Z.

Zhonghua Fu Chan Ke Za Zhi. 2006 Apr;41(4):237-41. Review. Chinese.

PMID:
16759457

Supplemental Content

Support Center